Lupin may test Rs 2600-2700: Prakash Diwan

Prakash Diwan of prakashdiwan.in told CNBC-TV18, "It is a belated re-rating of sorts that Lupin has had thanks to the slew of successful monetisation attempts by the company and as we go into an environment where the US government is going to focus more on reducing healthcare cost. Some of the products in the pipeline that Lupin has built over the period of time on the generics side would kind of help to continue this momentum.""My sense is Lupin will probably see a complete re-rating the way it happened to Ranbaxy and Sun Pharma a couple of years back and then that could mean it could see price levels of about Rs 2,600-2,700 very sooner on the stock without any kind of let up. So, this momentum is there to stay. If you probably missed out on the bus at Rs 1,800 kind of levels you could still get in but the momentum definitely is here to stay," he said.